Article Figures & Tables
Figures
- Fig. 1.
hiNSCs secrete virus, display an altered secretome and differentiation profile, and undergo apoptosis in response to ZIKV infection, which can be attenuated by Niclosamide treatment in vitro. (A) Infection rate of hiNSCs at different MOIs as determined by immunostaining against flavivirus envelope protein. Scale bar: 100 µM. (B) ELISA assay of secreted ZIKV NS1 protein in cell culture supernatants indicates that hiNSCs secrete increased ZIKV NS1 over time, which can be attenuated by pre- or concurrent NIC treatment. (C) Cytokine array data showing that hiNSCs secrete a variety of cytokines and growth factors. (D) qRT-PCR data indicating that NIC inhibits the expression of CXCL10, LIF and VEGF to varying degrees. (E) ZIKV affects the differentiation profile of hiNSCs. ZIKV infection causes hiNSCs to express higher levels of VGAT and lower levels of VGLUT2, and NIC partially restores the expression of VGAT to control levels. Scale bar: 100 µM. (F) ZIKV induces massive cell death in hiNSCs. By day 10, most hiNSCs are dead regardless of starting MOI. Panel shows immunostaining of mock or ZIKV-infected hiNSCs (MOI 0.0005). Pre- or concurrent NIC treatment can partially restore rate of Caspase3 expression to normal. Scale bar: 100 µM. *P≤0.05, **P≤0.01, ***P≤0.001; as determined by one-way ANOVA with post hoc Tukey test. Error bars show mean±s.d.
- Fig. 2.
Intracranial injection of ZIKV-infected hiNSCs into chick embryos results in microcephaly. Injection of ZIKV-infected hiNSCs results in microcephaly. (A) Schematic and image of intracranial injection. (B) Embryos injected with mock- (left) or ZIKV-infected (right) hiNSCs 10 days post-injection. (C) Coronal sections showing pan-neuronal Tuj1 immunostaining showing morphological characteristics. fb, forebrain; ot, optic tectum (midbrain); de, diencephalon; arrow, ventricle. Scale bar: 1 mM. (D) Immunostaining indicating presence of hiNSCs (HuNu+) in the developing brain of E12 chick embryos, which are also positive for Tuj1. Scale bar: 100 µM. (E) ZIKV-infected hiNSCs are also positive for anti-flavivirus marker (ZV). Scale bar: 100 µM.
- Fig. 3.
Systemic Niclosamide treatment can partially rescue ZIKV-induced reduction in cranial size in a humanized in vivo model. (A) Schematic diagram showing experimental timeline of injection of hiNSCs as well as systemic ZIKV infection and NIC treatment. Briefly, embryos were injected with hiNSCs intracranially and treated with the first dose of either vehicle or NIC via the CAM at E3. At E5, embryos were subjected to systemic ZIKV infection as well as the second dose of either vehicle or NIC via the CAM, and all embryos were harvested at E12. (B) Image of E12 embryos after treatment (left to right: Mock plus vehicle, ZIKV plus vehicle, ZIKV plus NIC). Quantification of body length (C), eye area (D) as well as morphological features of the cranium including length (E), width (F) and height (G) across treatments. *P≤0.05, **P≤0.01, ***P≤0.001; as determined by one-way ANOVA with post hoc Tukey test.
- Fig. 4.
Niclosamide treatment reduces ZIKV infection and altered differentiation of hiNSCs in vivo. (A) Tuj1 immunostaining through the intact cranium. fb, forebrain; arrow, 4th ventricle. Scale bar: 1 mM. Quantification of forebrain and 4th ventricle area across treatments. (B) Immunostaining showing co-localization of HuNu and ZV to quantify the number of ZIKV-infected hiNSCs. Scale bar: 50 µM. (C) Immunostaining showing co-localization of HuNu and CXCL10 with quantification. Scale bar: 50 µM. (D,E) Immunostaining showing co-localization of HuNu with either VGAT (D) to indicate the presence of GABAergic neurons or VGLUT2 (E) which indicates glutamatergic neurons, with respective quantification. Scale bar: 100 µM. *P≤0.05, **P≤0.01, ***P≤0.001; as determined by one-way ANOVA with post hoc Tukey test. Error bars show mean±s.d.
Article Navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
First person interview – Mary Salcedo
Have you seen our interviews with early-career first authors of our papers? In the latest issue, first author Mary Salcedo discusses her latest Methods and Techniques paper in which a newly created method geometrically analyses 789 insect wings.
Find out how Pamela Imperadore’s Travelling Fellowship grant from The Company of Biologists took her to Germany, where she used new imaging techniques to investigate the cellular machinery underlying octopus arm regeneration. Don’t miss the next application deadline for 2020 travel, coming up on 29 November. Where will your research take you?
On the cover, David Coppola, Brent Craven and their colleagues refute a widely-debated theory of olfactory coding first suggested by the Nobel Laureate Lord Adrian over half a century ago.
Biology Open has strong credentials and publishing with us is easy and fast. BiO aims to provide rapid publication for scientifically sound observations and valid conclusions in developmental, cell, experimental and translational biology. Submit your paper here – you’ll be in good company!
Recent cell science highlights in BiO – Masamitsu Sato and colleagues show that the conserved microtubule-associated protein CLASP facilitates bundling of spindle microtubules in early mitosis.
Transfer to Biology Open
If your submission to one of our sister journals, Development, Journal of Cell Science, Journal of Experimental Biology or Disease Models & Mechanisms, is unsuccessful, you can transfer your paper and any reviews directly to Biology Open. The majority of papers transferred with reviews are accepted for publication - find out more.
BiO joins the Review Commons initiative
Biology Open is pleased to be a part of the new and exciting Review Commons initiative, launched by EMBO and ASAPbio. Streamlining the publishing process, Review Commons enables high-quality peer review to take place before journal submission. Papers submitted to Review Commons will be assessed independently of any journal, focusing solely on the paper’s scientific rigor and merit.
preLights - Mammalian Y RNAs are modified at discrete guanosine residues with N-glycans
Connor Rosen discusses his selected preprint by Carolyn Bertozzi, Ryan Flynn and their co-workers on the glycosylation of small non-coding RNAs in mammalian cells.